Disease · MONDO_0004323

muscular atrophy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. muscular atrophy. Diseases, record MONDO_0004323. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004323

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: muscular atrophy; Open Targets
Open Targets ID: MONDO_0004323; Open Targets
Other names: Amyotrophy, Amyotrophy involving the extremities, Muscle atrophy, Muscle atrophy, neurogenic, Muscle degeneration, Muscle hypotrophy, Muscle wasting, Neurogenic muscle atrophy, Neurogenic muscle atrophy, especially in the lower limbs, Neurogenic muscular atrophy, Skeletal muscle atrophy; Open Targets
Disease Ontology: DOID:767; Disease Ontology
MeSH: D009133; MeSH
Highest stage of its drugs: Phase 2/3, for 1 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SOMATROPIN	CHEMBL1201621	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ENOBOSARM	CHEMBL1738889	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LANDOGROZUMAB	CHEMBL3545072	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TESAMORELIN	CHEMBL1237026	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PAMIDRONIC ACID	CHEMBL834	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
NANDROLONE DECANOATE	CHEMBL1200946	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
SIROLIMUS	CHEMBL413	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
AR	Androgen receptor	2	Androgen Receptor agonist; Androgen Receptor modulator	Phase 2	https://conductscience.org/library/genes/367	Drugs and targets
FDPS	Farnesyl pyrophosphate synthase	1	Farnesyl diphosphate synthase inhibitor	Phase 1	https://conductscience.org/library/genes/2224	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Unknown	https://conductscience.org/library/genes/2280	Drugs and targets
GHR	Growth hormone receptor	1	Growth hormone receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2690	Drugs and targets
GHRHR	Growth hormone-releasing hormone receptor	1	Growth hormone-releasing hormone receptor agonist	Phase 2	https://conductscience.org/library/genes/2692	Drugs and targets
MSTN	Growth/differentiation factor 8	1	Growth/differentiation factor 8 inhibitor	Phase 2	https://conductscience.org/library/genes/2660	Drugs and targets
MTNR1A	Melatonin receptor	1	Melatonin receptor agonist	Phase 2	https://conductscience.org/library/genes/4543	Drugs and targets
MTNR1B	Melatonin receptor	1	Melatonin receptor agonist	Phase 2	https://conductscience.org/library/genes/4544	Drugs and targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01604408	A Study in Older Participants Who Have Fallen and Have Muscle Weakness	Phase 2	201	2018-04-25	Muscle Weakness	LANDOGROZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00467844	Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.	Phase 2	159	2013-02-21	Cachexia	ENOBOSARM	Its record names the disease	ClinicalTrials.gov
NCT01388920	Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting	Phase 2	3	2014-05-07	Chronic Obstructive Pulmonary Disease (COPD)	TESAMORELIN	Its record names the disease	ClinicalTrials.gov
NCT03894683	Effect of Melatonin on Cardiovascular and Muscle Mass and Function in Patients With Heart Failure	Phase 2	90		Heart Failure With Reduced Ejection Fraction	MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT00250536	Anabolic Steroids and Exercise in Hemodialysis Patients	Not applicable	80		End-Stage Renal Disease, Muscle Weakness	NANDROLONE DECANOATE	Its record names the disease	ClinicalTrials.gov
NCT00311571	Toulouse Male Long Term Bed Rest 2001-2002	Phase 1	28		Simulation of Weightlessness by Anti-Orthostatic Long Term Bed Rest	PAMIDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT05414292	Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)	Not applicable	16		Muscle Atrophy, Age-Related Sarcopenia	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03038594	Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients	Phase 2/3	13		Burns, Growth Hormone Treatment	SOMATROPIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
LY2495655 vs Placebo: serious adverse events	27 of 102	18 of 99	201	NCT01604408

Source Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
16128698	RESULT	1	PubMed
15811637	RESULT	1	PubMed
15758301	RESULT	1	PubMed
15476576	RESULT	1	PubMed
15331681	RESULT	1	PubMed
15180967	RESULT	1	PubMed
15170571	RESULT	1	PubMed
15064323	RESULT	1	PubMed
15002526	RESULT	1	PubMed
40581981	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004323

GET https://conductscience.org/api/diseases/v1/MONDO_0004323/drugs

API reference For AI assistants